RGMA (Elezanumab Biosimilar) Recombinant Monoclonal Antibody

Code CSB-RA836186MB1HU
Size US$9799
Order now
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Uniprot No.
Target Names
Alternative Names
ABT-555 research-grade biosimilar; AE12-1Y-QL research-grade biosimilar; Elezanumab research-grade biosimilar; Elezanumab (USAN/INN) research-grade biosimilar; PR-1432051 research-grade biosimilar ;RGMA antibody; RGM antibody; Repulsive guidance molecule A antibody; RGM domain family member A antibody
Species Reactivity
Human
Immunogen
Recombinant Human RGMA protein
Immunogen Species
Homo sapiens (Human)
Conjugate
Non-conjugated
Clonality
Monoclonal
Concentration
It differs from different batches. Please contact us to confirm it.
Buffer
0.01M PBS,pH7.4
Form
Liquid
Troubleshooting and FAQs
Storage
Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Notes
Validation Status
Application-specific performance (e.g., in flow cytometry, ELISA, IHC or other assay formats) has not yet been experimentally verified by CUSABIO. Users are advised to determine the optimal working conditions empirically in their own assay systems.
Guaranteed Quality
① Antibody purity > 95% tested by SDS-PAGE.
② Endotoxin level < 0.1EU/ug tested by LAL method.
Lead Time
3-4 weeks
Description

This recombinant monoclonal antibody is a research-grade biosimilar to elezanumab, designed for research applications targeting repulsive guidance molecule A (RGMA). RGMA is a glycosylphosphatidylinositol-anchored protein that functions as an axonal growth inhibitor by binding to neogenin receptors. It plays a critical role in neural development and axon guidance during embryogenesis. In the adult central nervous system, RGMA contributes to the inhibition of axonal regeneration following injury and has been implicated in neurodegenerative conditions. Elevated RGMA expression has been associated with multiple sclerosis, spinal cord injury, and stroke, where it limits neuronal repair and functional recovery.

Elezanumab is a humanized IgG1 monoclonal antibody that neutralizes RGMA activity, thereby promoting axonal growth and potentially enhancing neural repair mechanisms. This biosimilar antibody serves as a valuable tool for investigating RGMA-mediated signaling pathways, studying axon regeneration mechanisms, and exploring therapeutic strategies for neurological disorders characterized by impaired neural plasticity. It enables researchers to examine the role of RGMA in disease models and evaluate potential neuroprotective interventions.

Usage
It is a non-therapeutic biosimilar antibody, owning the same variable region from the corresponding approved therapeutic antibody. In conclusion, it is a research-grade biosimilar antibody and expressed in mammalian cell, which can be directly used as positive controls in drug discovery or used for rapid verification of the biological functions of target protein.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
Member of the repulsive guidance molecule (RGM) family that performs several functions in the developing and adult nervous system. Regulates cephalic neural tube closure, inhibits neurite outgrowth and cortical neuron branching, and the formation of mature synapses. Binding to its receptor NEO1/neogenin induces activation of RHOA-ROCK1/Rho-kinase signaling pathway through UNC5B-ARHGEF12/LARG-PTK2/FAK1 cascade, leading to collapse of the neuronal growth cone and neurite outgrowth inhibition. Furthermore, RGMA binding to NEO1/neogenin leads to HRAS inactivation by influencing HRAS-PTK2/FAK1-AKT1 pathway. It also functions as a bone morphogenetic protein (BMP) coreceptor that may signal through SMAD1, SMAD5, and SMAD8.
Gene References into Functions
  1. Dysregulation of RGMa plays an important role in the pathology of Parkinson's disease. PMID: 28842419
  2. Thus, we conclude that RGMa inhibits angiogenesis in vitro and in vivo suggesting that its manipulation would be an efficient therapeutic strategy for pro-angiogenic conditions. PMID: 26721439
  3. RGMa expression and promoter methylation status are closely related to colorectal cancer genesis and progression. PMID: 22367090
  4. identification of neogenin-binding site on the repulsive guidance molecule A PMID: 22396795
  5. The expression of RGMA, RGMB and RGMC was evident in most examined prostate cancer cell lines, and also in the prostate cancer tissues PMID: 22076499
  6. Reduced expression of RGMA in breast cancer was associated with breast cancer. PMID: 21617229
  7. The full-length signal peptides of RGMa is functional and furthermore that the C-domains are sufficient and essential for ER targeting, whereas the N-domains are dispensable. Thus, the N-domains are available for additional functions. PMID: 21183991
  8. RGM-A is a unique endogenous inhibitor of leukocyte chemotaxis that limits inflammatory leukocyte traffic PMID: 21467223
  9. Following central nervous system injury, RGM, a novel, potent axonal growth inhibitor, is present in axonal growth impediments: the mature myelin, choroid plexus, and components of the developing scar. PMID: 16216939
  10. RGMa facilitates the use of ActRIIA by endogenous BMP2 and BMP4 ligands that otherwise prefer signaling via BMPRII and increased utilization of ActRIIA leads to generation of an enhanced BMP signal PMID: 17472960
  11. detected a homozygous deletion of chromosomal region 15q26.2 in the cell line HDLM2 encompasing RGMA and CHD2 PMID: 17606441
  12. this study, we show that Unc5B, a member of the netrin receptor family, interacts with neogenin as a coreceptor for RGMa. PMID: 19273616
  13. Frequent inactivation of axon guidance molecule RGMA in human colon cancer through genetic and epigenetic mechanisms. PMID: 19303019

Show More

Hide All

Subcellular Location
Cell membrane; Lipid-anchor, GPI-anchor.
Protein Families
Repulsive guidance molecule (RGM) family
Database Links

HGNC: 30308

OMIM: 607362

KEGG: hsa:56963

STRING: 9606.ENSP00000452126

UniGene: Hs.271277

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2026 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
Place an order now

I. Product details

*
*
*
*

II. Contact details

*
*

III. Ship To

*
*
*
*
*
*
*

IV. Bill To

*
*
*
*
*
*
*
*